Buy & Sell AbCellera Biologics Inc (ABCL) – AbCellera Biologics Inc Price Today

AbCellera Biologics (ABCL) trades at $4.145, down 0.36% on the day. The stock shows a bullish technical signal from moving averages, though key RSI indicators suggest overbought conditions. Fundamentally, the company is in a transition phase, pivoting to a pipeline-driven model with its lead candidate ABCL635 entering Phase 1 clinical data readout, as highlighted in a Business Wire announcement on April 20, 2026. However, financials reflect significant challenges, with revenue declining sharply to $28.83M in 2024 and net income deeply negative at -$162.86M, resulting in a net margin of -564.83%.

The outlook hinges on clinical execution and pipeline monetization, presenting high-risk, high-reward potential. Analyst sentiment is strongly bullish with an 81.82% buy rating, but investors face substantial risks from persistent cash burn, negative profitability, and the binary nature of clinical trial outcomes. The company's solid cash position of $625.61M provides a runway to fund operations.